Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of rheumatoid arthritis patients at study entry

From: Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis

Patients Responder Nonresponder P value
Number of patients 31 19  
Sex (male:female) 7:24 4:15 0.61
Mean (range) age (years) 55.8 (41 to 75) 55.9 (40 to 71) 0.97
Cardiovascular risk factors (≥1, % positive) 51.1 65.4 0.12
IgM-RF (% positive) 54.8 31.6 0.17
Anti-CCP (% positive) 64.5 31.6 0.15
Mean (standard deviation) DAS28 4.82 (±1.19) 5.30 (±1.55) 0.22
Mean (range) CRP (mg/l) 10.9 (2.0 to 114.5) 11.4 (2.0 to 80.7) 0.93
Mean (range) disease duration (years) 6.92 (2 to 29) 5.4 (1 to 19) 0.84
Therapy    
 Corticosteroids 23 11  
 DMARDs    
  Methotrexate 24 15  
  Leflunomide 7 4  
  1. Anti-CCP, anti-cyclic citrullinated peptide antibodies; CRP, C-reactive protein; DAS28, Disease activity score in 28 joints at study visit V1; DMARD, disease-modifying antirheumatic drug; RF, rheumatoid factor.